Glaukos Corporation
$171.68
$0.59 (+0.34%)
$167.97Day Range$172.76
Key Statistics
Market Cap
$10.13B
Shares Outstanding
59.0M
Primary Exchange
XNYS
Currency
USD
Type
CS
IPO Date
Jun 25, 2015
Round Lot
100
Locale
US
Trading Data
Day Open
$169.75
Day High
$172.76
Day Low
$167.97
Volume
621.7K
VWAP
$171.51
Prev Close
$171.09
Transactions
--
Acc. Volume
--
About Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
SURGICAL & MEDICAL INSTRUMENTS & APPARATUSSIC 38411,094 employees1 GLAUKOS WAY, ALISO VIEJO, CA, 92656949-367-9600IPO Jun 25, 2015US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001192448
- Composite FIGI
- BBG000WG2LQ1
- Share Class FIGI
- BBG001T91NX8
- Ticker Root
- GKOS
- SIC Code
- 3841
About Glaukos Corporation (GKOS) Stock
Glaukos Corporation (GKOS) closed the 2026-09-15 session at $171.68, up 0.34% versus the previous close (+0.59). The stock opened at $169.75 and traded between $167.97 and $172.76 during that session. Session trading volume was 622K shares. The volume-weighted average price (VWAP) is $171.51.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Glaukos Corporation has a market capitalization of $10.13 billion. The company operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry classification. GKOS is listed on the XNYS exchange. The company employs approximately 1,094 people. Glaukos Corporation is headquartered in ALISO VIEJO, CA. The recorded listing date is 2015-06-25.
On this page you can find market GKOS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector.